Carisma Therapeutics, Inc. (CARM)
NASDAQ: CARM · IEX Real-Time Price · USD
6.38
+0.53 (9.06%)
At close:
Jun 2, 2023, 4:00 PM
6.25
-0.13 (-2.04%)
After-hours:
Jun 2, 2023, 5:48 PM EDT
Carisma Therapeutics Stock Forecast
Stock Price Forecast
According to 2 stock analysts, the average 12-month stock price forecast for CARM stock stock is $10, which predicts an increase of 56.74%. On average, analysts rate CARM stock stock as a strong buy.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CARM stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '23 | May '23 |
|---|---|---|
| Strong Buy | 0 | 1 |
| Buy | 1 | 1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Total | 1 | 2 |
Financial Forecast
Revenue This Year
7.61M
from 40.00M
Decreased by
-80.97%
Revenue Next Year
7.61M
from 7.61M
EPS This Year
-1.90
from -2.00
EPS Next Year
-1.29
from -1.90
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 11.24M | 26.54M | 40.00M | 7.61M | 7.61M | - |
| Revenue Growth | - | - | - | 136.24% | 50.69% | -80.97% | - | - |
| EPS | -11.00 | -23.60 | -3.80 | - | -2.00 | -1.90 | -1.29 | -0.03 |
| EPS Growth | - | - | - | - | - | - | - | - |
| No. Analysts | - | - | - | - | - | 4 | 4 | 3 |
Revenue Forecast
| Revenue | 2023 | 2024 | 2025 |
|---|---|---|---|
| High | 15.7M | 15.7M | n/a |
| Avg | 7.6M | 7.6M | n/a |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2023 | 2024 | 2025 |
|---|---|---|---|
| High | -60.8%
| 105.9%
| - |
| Avg | -81.0%
| - | - |
| Low | - | - | - |
EPS Forecast
| EPS | 2023 | 2024 | 2025 |
|---|---|---|---|
| High | -1.89 | -0.63 | -0.03 |
| Avg | -1.90 | -1.29 | -0.03 |
| Low | -1.89 | -1.89 | -0.03 |
EPS Growth
| EPS Growth | 2023 | 2024 | 2025 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.